Standardizing care for hepatitis delta in the Netherlands
Official title: Standardising Care for Hepatitis Delta in the Netherlands
Run by Erasmus Medical Center · NCT05903742 · Data updated 2026-11-12
This study is trying to gather information from adults with hepatitis delta to better understand the disease and improve how it's treated.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 80 (estimated) |
| Sponsor | Erasmus Medical Center Academic / other |
| Locations | 1 site (Rotterdam) |
| Status | Recruiting |
| Started | January 22, 2024 |
| Main results expected | September 1, 2030 |
| Study ends | September 1, 2031 |
| Registry record updated | April 3, 2024 |
| Trial ID | NCT05903742 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 and older who have active hepatitis delta confirmed by specific blood tests.
✕Probably not a fit
Patients without active hepatitis delta or those under 18 years old may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to gather prospective follow-up data on patients with hepatitis delta, a rare and severe liver disease associated with hepatitis B virus. Over a five-year period, the study will collect standard clinical data, blood samples, and quality of life questionnaires from participants aged 18 and older. The goal is to enhance understanding of hepatitis delta and improve management practices, which currently vary due to the low incidence of the disease.
Why it matters
Potential benefit: If successful, this study could lead to improved care and management strategies for patients with hepatitis delta.
How similar studies have gone: While there is limited experience in managing hepatitis delta due to its rarity, this study aims to standardize care practices, which could be a novel approach in this field.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Active hepatitis delta based on a positive anti-HDV and a positive HDV-RNA test * Patients must be ≥18 years * Written informed consent Exclusion Criteria: * None
Where it's running
-
Erasmus MC
Rotterdam, Netherlands Recruiting
Study contacts
- Study coordinator: Lesley Patmore, MD
- Email: l.patmore@erasmusmc.nl
- Phone: +31629677982
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Oral and gum health and saliva markers in people with hepatitis B and D
This project will test whether gum inflammation and specific saliva and gum-fluid markers differ in adults with hepatitis B and D—both those taking bulevirtide and those not—compared with healthy adults.
-
Long-term treatment with Bulevirtide for patients with Hepatitis D-related cirrhosis
This study is testing if a medication called Bulevirtide can help people with Hepatitis D-related cirrhosis improve their health over a long period of time.
-
Effect of Bulevirtide on Chronic Hepatitis Delta in Italy
This study is testing if the medication Bulevirtide can help people with Chronic Hepatitis Delta in Italy feel better and improve their health.
-
Observational study on Hepatitis D patients in France
This study looks at Hepatitis D patients in France to see how many are being tested and treated, and aims to find ways to make it easier for them to get the care they need.
-
Evaluation of patients with liver disease
This study is trying to learn more about liver diseases by checking in on patients with conditions like hepatitis B, C, and D through regular tests and follow-ups.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.